Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.
CONCLUSION: Evolocumab was superior to ezetimibe in reducing LDL-C during the 12-week double-blind period in this population of Japanese patients with statin intolerance, with efficacy and safety results maintained for 1 year.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT02634580.
PMID: 31748467 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Common Cold | Heart | Japan Health | Rhabdomyolysis | Statin Therapy | Study | Thrombosis | Vytorin | Zetia